ReviewViruses2020
Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?
Review in Viruses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 57 citations in OpenAlex.
- Investigation of the administration technique and side effects of COVID-19 vaccines: a descriptive and cross-sectional study.Scientific reports · 2026Article
- Article
- Self-reported side effects of COVID-19 vaccines among the public.Journal of pharmaceutical policy and practice · 2024Article
- COVID-19 Incidence Proportion as a Function of Regional Testing Strategy, Vaccination Coverage, and Vaccine Type.Viruses · 2023Article
- Article
- The Effect of Intra-articular Corticosteroid Injections on Vaccine Efficacy: A Current Concepts Review.The archives of bone and joint surgery · 2023Review
- Cytokine Receptor Allele Frequency, Immunogenicity, and Efficacy of New COVID-19 Vaccine in Different Setting.International journal of preventive medicine · 2023Article
- COVID-19 Vaccination Prioritization Strategies in Malaysia: A Retrospective Analysis of Early Evidence.Vaccines · 2022Review
- Medicine and health of 21st Century: Not just a high biotech-driven solution.NPJ genomic medicine · 2022Review
- Patent intelligence of RNA viruses: Implications for combating emerging and re-emerging RNA virus based infectious diseases.International journal of biological macromolecules · 2022Article
- Comprehensive Highlights of the Universal Efforts towards the Development of COVID-19 Vaccine.Vaccines · 2022Review
- COVID-19 Vaccinating Russian Medical Students-Challenges and Solutions: A Cross-Sectional Study.International journal of environmental research and public health · 2022Article
- Identification of potential SARS-CoV-2 MJournal of biomolecular structure & dynamics · 2022Article
- Current advances and challenges in COVID-19 vaccine development: from conventional vaccines to next-generation vaccine platforms.Molecular biology reports · 2022Review
- Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges.Pharmaceutics · 2022Review
- Developing an Effective Peptide-Based Vaccine for COVID-19: Preliminary Studies in Mice Models.Viruses · 2022Article
- Anti-vaccination movements in the world and in Brazil.Revista da Sociedade Brasileira de Medicina Tropical · 2022Article
- The COVID-19 vaccine and interventional procedures: Exploring the relationship between steroid administration and subsequent vaccine efficacy.Pain practice : the official journal of World Institute of Pain · 2021Review
- Global Scientific Research on SARS-CoV-2 Vaccines: A Bibliometric Analysis.Cell journal · 2021Article
- Mosaic vaccination: How distributing different vaccines across a population could improve epidemic control.Evolution letters · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Seven years after the Middle East respiratory syndrome (MERS) outbreak, a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) made its first appearance in a food market in Wuhan, China, drawing an entirely new course to our lives. As the virus belongs to the same genus of MERS and SARS, researchers have been trying to draw lessons from previous outbreaks to find a potential cure. Although there were five Phase I human vaccine trials against SARS and MERS, the lack of data in humans provided us with limited benchmarks that could help us design a new vaccine for Coronavirus disease 2019 (COVID-19). In this review, we showcase the similarities in structures of virus components between SARS-CoV, MERS-CoV, and SARS-CoV-2 in areas relevant to vaccine design. Using the ClinicalTrials.gov and World Health Organization (WHO) databases, we shed light on the 16 current approved clinical trials worldwide in search for a COVID-19 vaccine. The different vaccine platforms being tested are Bacillus Calmette-Guérin (BCG) vaccines, DNA and RNA-based vaccines, inactivated vaccines, protein subunits, and viral vectors. By thoroughly analyzing different trials and platforms, we also discuss the advantages and disadvantages of using each type of vaccine and how they can contribute to the design of an adequate vaccine for COVID-19. Studying past efforts invested in conducting vaccine trials for MERS and SARS will provide vital insights regarding the best approach to designing an effective vaccine against COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.